Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5532]

Daraxonrasib plus chemotherapy shows promising first-line activity in RAS...

Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA

Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer ( Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA )

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas

Dr Rohit Thummalapalli - Memorial Sloan Kettering Cancer Center, New York, USA

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas ( Dr Rohit Thummalapalli - Memorial Sloan Kettering Cancer Center, New York, USA )

DLL3 expression in circulating tumour cells predicts response to tarlatamab in...

Dr Avanish Mishra - Krantz Family Center for Cancer Research, Boston, USA

DLL3 expression in circulating tumour cells predicts response to tarlatamab in small cell lung cancer ( Dr Avanish Mishra - Krantz Family Center for Cancer Research, Boston, USA )

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in...

Dr Manuel Hidalgo - NYU Langone Health, New York, USA

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer ( Dr Manuel Hidalgo - NYU Langone Health, New York, USA )

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal...

Dr Michael Foote - Memorial Sloan Kettering Cancer Cente, New York City, USA

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer ( Dr Michael Foote - Memorial Sloan Kettering Cancer Cente, New York City, USA )

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck...

Dr Enrique Sanz-Garcia - UHN Princess Margaret Cancer Centre, Toronto, Canada

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer ( Dr Enrique Sanz-Garcia - UHN Princess Margaret Cancer Centre, Toronto, Canada )

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC ( Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain )

mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity

Prof Rana McKay - University of California San Diego, San Diego, USA

mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity ( Prof Rana McKay - University of California San Diego, San Diego, USA )

Development and challenges for T-cell engagers as a novel treatment for lung...

Dr May-Lucie Meyer - Lausanne University Hospital, Lausanne, Switzerland

Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma ( Dr May-Lucie Meyer - Lausanne University Hospital, Lausanne, Switzerland )

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

Dr Miranda Gogishvili - High Technology Medical Centre, Tbilisi, Georgia

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC ( Dr Miranda Gogishvili - High Technology Medical Centre, Tbilisi, Georgia )

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated...

Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer ( Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA )

Durvalumab plus chemotherapy improves survival in extensive-stage small cell...

Dr Lorenza Landi - National Cancer Institute Regina Elena, Rome, Italy

Durvalumab plus chemotherapy improves survival in extensive-stage small cell lung cancer regardless of tumour laterality ( Dr Lorenza Landi - National Cancer Institute Regina Elena, Rome, Italy )

More from ecancer